GlobeNewswire
Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb
📊
AI Sentiment
Positive
7/10
Bristol-Myers Squibb Company News
Latest updates and market news for BMY
20 news
Dec 3 - Dec 9, 2025
Page 1
MT Newswires
BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment
📊
AI Sentiment
Positive
6/10
Business Wire
Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
📈
AI Sentiment
Highly Positive
9/10
Zacks
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
📊
AI Sentiment
Positive
7/10
MT Newswires
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog
➖
AI Sentiment
Neutral
5/10
Insider Monkey
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
➖
AI Sentiment
Neutral
5/10
Zacks
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
📈
AI Sentiment
Highly Positive
8/10
BioPharma Dive
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Bristol-Myers Says FDA Approves Breyanzi for Marginal Zone Lymphoma Treatment
📊
AI Sentiment
Positive
7/10
Business Wire
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Tigerlily Foundation Launches the "Bliss Collective: Brunch & Sip" Series to Empower, Educate, and Uplift Women Nationwide
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $53 From $45, Maintains Sector Perform Rating
➖
AI Sentiment
Neutral
5/10
Share this news page